1063 related articles for article (PubMed ID: 11801536)
21. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
22. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
[TBL] [Abstract][Full Text] [Related]
23. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
24. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
25. Erythroblasts highly express the ABC transporter Bcrp1/ABCG2 but do not show the side population (SP) phenotype.
Yamamoto K; Suzu S; Yoshidomi Y; Hiyoshi M; Harada H; Okada S
Immunol Lett; 2007 Nov; 114(1):52-8. PubMed ID: 17905444
[TBL] [Abstract][Full Text] [Related]
26. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
Ozvegy C; Váradi A; Sarkadi B
J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
[TBL] [Abstract][Full Text] [Related]
27. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
28. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer.
Xie ZY; Lv K; Xiong Y; Guo WH
Oncol Res Treat; 2014; 37(11):666-8, 670-2. PubMed ID: 25427584
[TBL] [Abstract][Full Text] [Related]
29. Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone.
Nieth C; Lage H
J Chemother; 2005 Apr; 17(2):215-23. PubMed ID: 15920909
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.
Mosaffa F; Lage H; Afshari JT; Behravan J
Inflamm Res; 2009 Oct; 58(10):669-76. PubMed ID: 19333723
[TBL] [Abstract][Full Text] [Related]
31. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
32. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
[TBL] [Abstract][Full Text] [Related]
33. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
34. Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines.
Taheri T; Jamialahmadi K; Khadijeh F
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3413-3418. PubMed ID: 29286612
[TBL] [Abstract][Full Text] [Related]
35. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
[TBL] [Abstract][Full Text] [Related]
36. The presence of ABCG2-dependent side population cells in human periodontal ligaments.
Kawanabe N; Murakami K; Takano-Yamamoto T
Biochem Biophys Res Commun; 2006 Jun; 344(4):1278-83. PubMed ID: 16650829
[TBL] [Abstract][Full Text] [Related]
37. Role of the ATP-binding cassette transporter Abcg2 in the phenotype and function of cardiac side population cells.
Pfister O; Oikonomopoulos A; Sereti KI; Sohn RL; Cullen D; Fine GC; Mouquet F; Westerman K; Liao R
Circ Res; 2008 Oct; 103(8):825-35. PubMed ID: 18787193
[TBL] [Abstract][Full Text] [Related]
38. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
[TBL] [Abstract][Full Text] [Related]
39. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
Litman T; Brangi M; Hudson E; Fetsch P; Abati A; Ross DD; Miyake K; Resau JH; Bates SE
J Cell Sci; 2000 Jun; 113 ( Pt 11)():2011-21. PubMed ID: 10806112
[TBL] [Abstract][Full Text] [Related]
40. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]